DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Miles D, Puglisi F, Schneeweiss A, Ciruelos E, Peretz-Yablonski T, Moreno K. et al.
1816 preliminary safety results from PERUSE, a study of 1436 patients (pts) treated with first-line pertuzumab (P) combined with trastuzumab (H) and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC).
Eur J Cancer 2015;
51: S
Access:
We do not assume any responsibility for the contents of the web pages of other providers.